Lymphoma Research Funded by LLS

Our investment in lymphoma research has led to significant advances, such as rituximab (Rituxan®) and innovative immunotherapy, such as the first first chimeric antigen receptor (CAR) T-cell-therapy approved by the FDA for lymphoma patients: axicabtagene ciloleucel (Yescarta®). Our current lymphoma research commitment exceeds $73 million, so we can continue to bring promising new treatments to patients.

Lymphoma encompasses a variety of cancers of the lymphatic system and it is a very common hematologic malignancy, making up around a third of all new blood cancer cases in the US and in Europe. It is the most common blood cancer in the United States, and accounts for about 5% of all cancers. 

There are many different types of lymphomas, but the two main groups are Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Both types can occur in either children or adults.


Are you a Patient or Caregiver? Click here for our free informational booklet on Lymphomas.



Lymphoma Subtypes

Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is derived from white blood cells that grow in an uncontrolled, rapid manner and therefore require treatment. It is the most common form of lymphoma, comprising more than 25 percent of all lymphomas reported in the US (more than 25,000 cases of DLBCL diagnosed per year). While much progress has been made in treating the disease, many, but not all patients benefit from these treat...

Hodgkin Lymphoma (HL)

Hodgkin lymphoma (HL) is a subtype of lymphoma resulting from change in the DNA of a type of white blood cell known as a lymphocyte and is characterized by the presence of a cell known as the Reed-Sternberg cell.  HL is a highly treatable and there are numerous treatments approved, including a few novel, targeted agents. However, for the 20 to 30 percent of HL patients who relapse, new treatment options are stil...

Chronic Lymphocytic Leukemia (CLL)

Over the past 10 years, The Leukemia & Lymphoma Society (LLS) has invested more than $52 million to accelerate pioneering research in chronic lymphocytic leukemia (CLL), a blood cancer characterized by the development of too many white blood cells called lymphocytes. Our investment has unlocked new insights on CLL disease mechanisms and advanced new therapies to improve outcomes and care for patients.. Despite it...

Mantle cell lymphoma (MCL)

Mantle cell lymphoma (MCL), one of the 70 subtypes of non-Hodgkin lymphoma, results from a malignant change of a B lymphocyte within a lymph node. It is a particularly aggressive disease, with a short remission from standard therapies and a median overall survival of four to five years. LLS is supporting multiple approach to address the unmet need in this disease. Approximately 10-15% of MCL patients are considere...